Pearce IP BioBlast®: w/e 04 June 2021

by , | Jun 7, 2021

31 May 21 | Celltrion will launch Yuflyma® (biosimilar adalimumab) in the EU in June, as reported by the Korea Herald.  Citing ‘industry sources’ and a Celltrion official, the Korea Herald discloses that Celltrion will initially launch Yuflyma® in six EU countries including Spain, before launching in an additional 7 EU countries in Q3 2021, and 3 more in Q4 2021.

01 June 21 | Celltrion presented one-year data for Yuflyma® (biosimilar adalimumab). Celltrion reported that this data demonstrates comparable efficacy and safety to the reference product in patients with rheumatoid arthritis.

01 June 21 | Biogen and Bio-Thera announced results from Ph III trials of BAT1806 (proposed tocilizumab biosimilar) demonstrating equivalence to the reference product in patients with rheumatoid arthritis.

02 June 21 | US | Lupin announced the FDA has accepted the BLA for its proposed pegfilgrastim biosimilar.

Did you know that you can subscribe to Pearce IP’s updates including our weekly BioBlast® and regular pharma and IP industry news? Click here to receive these updates directly in your inbox.





Print Page Mail Article

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News